The research collaboration “New Targeting Vaccines for Sustainable Aquaculture” has received a grant of NOK 10 million through the Norwegian Research Council’s program Biotek2021. The NOK 10 million will be awarded over three years. Oslo Cancer Cluster member Vaccibody is a partner in the project with the Norwegian Veterinary Institute, Pharmaq AS, Kjeller Innovasjon and Kongla AS.
Researchers are focusing on developing customized, targeted fish vaccines based on the Vaccibody principle. “We are very pleased to be a part of this collaboration and for the funding it will receive from the Norwegian Research Council,” says Tom Pike, chairman and acting CEO of Vaccibody.
The fish farming industry is contending with different infections and theVaccibody technology is designed to address the problem in a sustainable manner, without antibiotics. “We are also proud to work with a consortium of well-qualified partners,” Pike adds. “The project fits well with Vaccibody’s strategy to develop its technology platform together with partners while focusing the main share of its internal resources on the development of VB10.16, a therapeutic DNA vaccine to treat precancerous lesions of the cervix currently entering Phase I/IIa.”
Source: Oslo Cancer Cluster